S-l-o-w Eddie's performance reviewIt's funny if you
look back one year and see where things stood for Acerus at the end of 2021.
You could pretend, as the late Southern Tier Tom used to do, that Tefina was going to be lauched for female anhedonia.
You could say that the strategy to concentrate on the USA market might pay off, that H.C. Wainwright might find some new investors, that an aquisition would turn things around, that approvals for Avanafil were just around the corner, that manufacturing problems for Natesto would be solved, that a 200-to-one reverse split in ASP stock would make sense, that Melnyk might try to arrange some scheme to take back the company, that Covid ending would mean that 2022 would be the Year of Acerus.
Instead, the stock is down to 4/10ths of a cent at pre-consolidation pricing, meaning that 90% of shareholder value was wiped out during the last 12 months. The staff is heading for the hills. Ian's reluctantly doling out his hoard of Canadian Tire currency once a month to make payroll.
Those are some incredible non-acheivements, and it says to me that based on this record Edward Gudaitis will go down as the worst-performing pharmaceutical executive in all of recorded history. No doubt he's arranging his exit package as we speak. And good f***ing riddance.